BTIG Reiterates Buy on Medline, Maintains $55 Price Target
BTIG analyst David Larsen reiterates Medline (NASDAQ:MDLN) with a Buy and maintains $55 price target.
Read original at benzingaStocks · News reference
Medline shares are trading lower despite reporting better-than-expected Q2 financial results. The decline may be related to a softer adjusted EBITDA outlook, as management cited higher-than-expected inflationary pressures stemming from the Middle East conflict.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 4:35 PM
- Checked
- Aug 5, 2026, 4:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Reported Earlier, FDA Says Medline Issued Correction For Convenience Kits Containing B. Braun Bupivacaine Hydrochloride Components, Identified As Most Serious Recall Type; B. Braun Reported 35 Serious Injuries, No Deaths
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/convenience-kit-recall-medline-issues-correction-convenience-kits-containing-b-braun-bupivacaine
Read original at benzingaMedline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products
FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.
Read original at benzingaJP Morgan Maintains Overweight on Medline, Lowers Price Target to $46
JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.
Read original at benzinga